slinghook67
Nov 16, 3:17 PM
$MGTX Great news for Ollin but this is pretty remarkable and once again speaks to how significantly undervalued Meira is. Ollin only has 2 assets, one is Phase 1 and the 2nd hasn't officially started Phase 3. And their lead asset, while showing very strong efficacy to date, if approved will enter a brutally competitive market and given that, their peak annual sales potential is falling in the range of
$1.5b-
$2B. And, they do not own any manufacturing assets.
Again, this is fantastic news for Ollin but contrast this purchase price with the totality of Meira's enterprise assets and our current market cap, and one can only imagine what our buyout price will be if Bota-Vec and Xerostomia trend towards regulatory approval. Not to mention Parkinson's & Riboswitch.....
0 replies